November 14, 2003

FOR: ZOLL Medical Corporation

Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832



Friday, November 14, 2003 – ZOLL Medical Corporation (NASDAQ: ZOLL) noted at the MassMEDIC MedTech Investors Conference today that its AED Plus™ automated external defibrillator meets challenges uncovered during the Public Access Defibrillation (PAD) Trial. The results of this study, funded by the National Heart, Lung, and Blood Institute, in collaboration with the American Heart Association (AHA), were announced at this week’s AHA Scientific Sessions.

PAD Trial investigators found that instructing lay volunteers in the use of AEDs and cardiopulmonary resuscitation (CPR) doubles survival rates, when compared to care provided by those who only had CPR training. In addition, investigators found that many CPR skills significantly eroded when volunteers were tested a year after their initial training.

“Issues uncovered during the trial confirm what ZOLL has recognized for some time—CPR is as important as early defibrillation in cardiac arrest cases that occur outside the hospital,” said Richard A. Packer, President and Chief Executive Officer of ZOLL. “This study shows a need for products that take rescuers through the entire resuscitation process. While other AEDs just defibrillate, the ZOLL AED Plus is the only public access defibrillator available today that guides rescuers with visual and audio prompts through the entire AHA Chain of Survival. This includes early access to medical care (calling 911), CPR, defibrillation, and supporting victims prior to the arrival of advanced care.”

Mr. Packer also noted, “It is well-established that the retention of CPR skills is poor and that inadequate rate and compression depth are common errors. ZOLL’s AED Plus is the only AED with instantaneous audio feedback that helps rescuers achieve the AHA-recommended depth and rate of compression, improving life-saving efforts.”

The AED Plus with CPR Feedback has a unique one-piece pre-connected electrode, called the CPR-D•padz™. It applies easily to a patient’s chest and simplifies placement for infrequent rescuers. Its patented technology offers an unmatched four-year shelf life, twice that of others on the market. The CPR-D•padz includes a hand-placement locator and accurately measures CPR compressions. Audio feedback tells a rescuer, “Press Harder” or “Good Compressions.”

The AED Plus is the only device to use easily obtained lithium camera batteries. It is immediately recognized by its distinct lime-green color, which was chosen for its association with safety, calming effect on the rescuer, and its ability to be easily seen. The AED Plus is reasonably priced to help as many communities as possible to implement early defibrillation programs in public places.

About ZOLL

ZOLL Medical Corporation (NASDAQ: ZOLL), with worldwide headquarters in Chelmsford, Massachusetts, designs, manufactures, and markets resuscitation solutions. Pacing and defibrillation devices, including ZOLL’s M Series and AED Plus, and LIFECOR, Inc.’s LifeVest™ Wearable Defibrillator; and circulatory assist devices such as Advanced Circulatory Systems, Inc.’s ResQPOD™ Circulatory Enhancer and Revivant Corporation’s AutoPulse™; are used by health care professionals, emergency medical service providers, and first responders to diagnose and treat cardiac arrest wherever it may occur. ZOLL also designs and markets software that automates the collection and management of both clinical and non-clinical data. ZOLL has operations in the United States, Canada, the United Kingdom, Germany, France, the Netherlands, and Australia, and business partners in all of the world’s major markets. For more information about ZOLL, its products and partners, visit or call 978-421-9655.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, the anticipated growth in the hospital market, our ability to grow AED sales and increase AED market share, our outlook for the Company, our anticipated sales and earnings growth, our beliefs regarding the North American market, our ability to successfully build our AED business and our ability to grow our International sales, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2003, including the future performance of the direct sales operations, as well as uncertainties regarding the market acceptance and profitability of the ZOLL AED Plus, the length and severity of the current economic slowdown and its impact on capital spending budgets, the reduction in overall capital equipment expenditures in the hospital and pre-hospital markets, the impact of governmental budget restraints on the purchase of capital equipment, the continued war in the Middle East, the impact of the war on terrorism, the potential disruption in the transportation industry on the Company’s supply chain and product distribution channels, and the desire or ability of other parties to purchase the Company's products.

# # #

Copyright © 2003 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105.
All trademarks are property of their respective owners.